XenoTherapeutics
Enfield, US · Founded 2019 · Delaware corporation
XenoTherapeutics develops regenerative medicine therapies derived from genetically engineered pigs as a living donor source, aiming to replace human cadaver tissue. Its first product, realSKIN, is a living skin transplant intended to support healing after severe injury.
Founders & leadership
XenoTherapeutics was founded in 2019 by Paul Holzer.
Reported raises · per SEC filings
Form D private placements$2M disclosed across 2 rounds · 2019–2021
▶$1.3MraisedApr 2021 · 8 investors · BiotechnologyRule 506(b)
▶$1.3MraisedApr 2021 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Krysta MoultonExecutive Officer, Director
- Paul HolzerExecutive Officer, Director
- Jon AdkinsExecutive Officer, Director
- Offering amount
- $8M
- Amount sold
- $1.3M
- Minimum investment
- $25K
- Proceeds to insiders
- $1.5M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$700.1KraisedJun 2019 · 5 investors · BiotechnologyRule 506(b)
▶$700.1KraisedJun 2019 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Krysta MoultonExecutive Officer, Director
- Paul HolzerExecutive Officer, Director
- Jon AdkinsExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $700.1K
- Proceeds to insiders
- $600K
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Xenon Pharma8 shared keywordsXenon is a neuroscience-focused biopharmaceutical company that discovers and develops ion channel modulators as therapeutics for neurological and psychiatric disorders. Its pipeline includes a Phase 3 program in epilepsy and depression for its lead candidate azetukalner, along with early-stage pain programs targeting sodium and potassium channels.
Bioworld6 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with XenoTherapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does XenoTherapeutics do?
- XenoTherapeutics develops regenerative medicine therapies derived from genetically engineered pigs as a living donor source, aiming to replace human cadaver tissue. Its first product, realSKIN, is a living skin transplant intended to support healing after severe injury.
- Who founded XenoTherapeutics?
- XenoTherapeutics was founded by Paul Holzer in 2019.
- How much funding has XenoTherapeutics raised?
- XenoTherapeutics has disclosed $2M raised across 2 rounds.
- Where is XenoTherapeutics headquartered?
- XenoTherapeutics is headquartered in Enfield, US.